Literature DB >> 9864282

The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.

D M Gentile1, C H Verhoeven, T Shimada, D J Back.   

Abstract

Desogestrel is a 3-deoxo progestogenic steroid that requires bioactivation to 3-ketodesogestrel. In these studies we have attempted to define the pathway of 3-ketodesogestrel formation and characterise the enzymes responsible for this biotransformation in vitro. Initial studies using deuterated desogestrel confirmed that desogestrel is metabolised by human liver microsomes via 3alpha-hydroxy and 3beta-hydroxydesogestrel to 3-ketodesogestrel. Metabolites were analysed by radiometric high-performance liquid chromatography and were identified by liquid chromatography-mass spectrometry and by cochromatography with authentic standards. Desogestrel was metabolised by microsomes from lymphoblasts containing cDNA-expressed CYP2C9 and CYP2C19 to 3alpha-hydroxydesogestrel with small amounts of 3beta-hydroxydesogestrel also being observed. The Km value for 3alpha-hydroxylation by CYP2C9 cell line microsomes was 6.5 microM and the corresponding Vmax value was 1269 pmole. mg-1. min-1. Sulfaphenazole potently inhibited 3alpha-hydroxydesogestrel formation by CYP2C9 microsomes with a Ki value of 0.91 microM. There was a significant negative correlation between 3-ketodesogestrel and CYP3A4 content/activity in a panel of human livers suggesting that the further metabolism of 3-ketodesogestrel is mediated by CYP3A4. Sulfaphenazole partially inhibited 3alpha-hydroxydesogestrel and 3-ketodesogestrel formation in human liver microsomes indicating a possible in vivo role for CYP2C9. In addition, when sulfaphenazole was combined with S-mephenytoin, further inhibition of 3alpha-hydroxydesogestrel formation was observed suggesting a possible role for CYP2C19. This was confirmed in incubations with inhibitory antibodies. Whereas an anti-CYP2C9/2C19 antibody completely abolished desogestrel metabolism, anti-CYP3A4 and anti-CYP2E1 were not inhibitory. We conclude that CYP2C9 and possibly CYP2C19 and important isoforms catalysing the initial hydroxylation of desogestrel.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Desogestrel; Enzymes; Enzymes And Enzyme Inhibitors; Family Planning; In Vitro; Physiology; Research Methodology; Research Report

Mesh:

Substances:

Year:  1998        PMID: 9864282

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.

Authors:  Tuomas Korhonen; Ari Tolonen; Jouko Uusitalo; Stefan Lundgren; Jorma Jalonen; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

Review 2.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

Review 3.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

Review 4.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.

Authors:  Liane Will-Shahab; Steffen Bauer; Ullrich Kunter; Ivar Roots; Axel Brattström
Journal:  Eur J Clin Pharmacol       Date:  2008-11-18       Impact factor: 2.953

Review 6.  Hyperforin in St. John's wort drug interactions.

Authors:  Rajanikanth Madabushi; Bruno Frank; Bernd Drewelow; Hartmut Derendorf; Veronika Butterweck
Journal:  Eur J Clin Pharmacol       Date:  2006-02-14       Impact factor: 2.953

7.  Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.

Authors:  Arabelle Pfrunder; Monika Schiesser; Simone Gerber; Manuel Haschke; Johannes Bitzer; Juergen Drewe
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 8.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.